These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
272 related articles for article (PubMed ID: 29490948)
1. YAP1-Mediated Suppression of USP31 Enhances NFκB Activity to Promote Sarcomagenesis. Ye S; Lawlor MA; Rivera-Reyes A; Egolf S; Chor S; Pak K; Ciotti GE; Lee AC; Marino GE; Shah J; Niedzwicki D; Weber K; Park PMC; Alam MZ; Grazioli A; Haldar M; Xu M; Perry JA; Qi J; Eisinger-Mathason TSK Cancer Res; 2018 May; 78(10):2705-2720. PubMed ID: 29490948 [TBL] [Abstract][Full Text] [Related]
2. YAP1 enhances NF-κB-dependent and independent effects on clock-mediated unfolded protein responses and autophagy in sarcoma. Rivera-Reyes A; Ye S; E Marino G; Egolf S; E Ciotti G; Chor S; Liu Y; Posimo JM; Park PMC; Pak K; Babichev Y; Sostre-Colón J; Tameire F; Leli NM; Koumenis C; C Brady D; Mancuso A; Weber K; Gladdy R; Qi J; Eisinger-Mathason TSK Cell Death Dis; 2018 Oct; 9(11):1108. PubMed ID: 30382078 [TBL] [Abstract][Full Text] [Related]
3. Targeting Hippo coactivator YAP1 through BET bromodomain inhibition in esophageal adenocarcinoma. Song S; Li Y; Xu Y; Ma L; Pool Pizzi M; Jin J; Scott AW; Huo L; Wang Y; Lee JH; Bhutani MS; Weston B; Shanbhag ND; Johnson RL; Ajani JA Mol Oncol; 2020 Jun; 14(6):1410-1426. PubMed ID: 32175692 [TBL] [Abstract][Full Text] [Related]
4. TGFβ and Hippo Pathways Cooperate to Enhance Sarcomagenesis and Metastasis through the Hyaluronan-Mediated Motility Receptor (HMMR). Ye S; Liu Y; Fuller AM; Katti R; Ciotti GE; Chor S; Alam MZ; Devalaraja S; Lorent K; Weber K; Haldar M; Pack MA; Eisinger-Mathason TSK Mol Cancer Res; 2020 Apr; 18(4):560-573. PubMed ID: 31988250 [TBL] [Abstract][Full Text] [Related]
5. Angiomotin regulates prostate cancer cell proliferation by signaling through the Hippo-YAP pathway. Zeng H; Ortiz A; Shen PF; Cheng CJ; Lee YC; Yu G; Lin SC; Creighton CJ; Yu-Lee LY; Lin SH Oncotarget; 2017 Feb; 8(6):10145-10160. PubMed ID: 28052036 [TBL] [Abstract][Full Text] [Related]
6. TAZ and YAP are frequently activated oncoproteins in sarcomas. Fullenkamp CA; Hall SL; Jaber OI; Pakalniskis BL; Savage EC; Savage JM; Ofori-Amanfo GK; Lambertz AM; Ivins SD; Stipp CS; Miller BJ; Milhem MM; Tanas MR Oncotarget; 2016 May; 7(21):30094-108. PubMed ID: 27129148 [TBL] [Abstract][Full Text] [Related]
7. The p130 isoform of angiomotin is required for Yap-mediated hepatic epithelial cell proliferation and tumorigenesis. Yi C; Shen Z; Stemmer-Rachamimov A; Dawany N; Troutman S; Showe LC; Liu Q; Shimono A; Sudol M; Holmgren L; Stanger BZ; Kissil JL Sci Signal; 2013 Sep; 6(291):ra77. PubMed ID: 24003254 [TBL] [Abstract][Full Text] [Related]
8. AMOTL1 enhances YAP1 stability and promotes YAP1-driven gastric oncogenesis. Zhou Y; Zhang J; Li H; Huang T; Wong CC; Wu F; Wu M; Weng N; Liu L; Cheng ASL; Yu J; Wong N; Lo KW; Tang PMK; Kang W; To KF Oncogene; 2020 May; 39(22):4375-4389. PubMed ID: 32313226 [TBL] [Abstract][Full Text] [Related]
9. Prevalence of the Hippo Effectors YAP1/TAZ in Tumors of Soft Tissue and Bone. Isfort I; Elges S; Cyra M; Berthold R; Renner M; Mechtersheimer G; Åman P; Larsson O; Ratner N; Hafner S; Simmet T; Schliemann C; Rossig C; Dirksen U; Grünewald I; Wardelmann E; Huss S; Hartmann W; Trautmann M Sci Rep; 2019 Dec; 9(1):19704. PubMed ID: 31873172 [TBL] [Abstract][Full Text] [Related]
10. Targeting Hippo-Dependent and Hippo-Independent YAP1 Signaling for the Treatment of Childhood Rhabdomyosarcoma. Slemmons KK; Yeung C; Baumgart JT; Juarez JOM; McCalla A; Helman LJ Cancer Res; 2020 Jul; 80(14):3046-3056. PubMed ID: 32354737 [TBL] [Abstract][Full Text] [Related]
11. αE-catenin inhibits a Src-YAP1 oncogenic module that couples tyrosine kinases and the effector of Hippo signaling pathway. Li P; Silvis MR; Honaker Y; Lien WH; Arron ST; Vasioukhin V Genes Dev; 2016 Apr; 30(7):798-811. PubMed ID: 27013234 [TBL] [Abstract][Full Text] [Related]
12. Angiomotin decreases lung cancer progression by sequestering oncogenic YAP/TAZ and decreasing Cyr61 expression. Hsu YL; Hung JY; Chou SH; Huang MS; Tsai MJ; Lin YS; Chiang SY; Ho YW; Wu CY; Kuo PL Oncogene; 2015 Jul; 34(31):4056-68. PubMed ID: 25381822 [TBL] [Abstract][Full Text] [Related]
13. miR-375 is involved in Hippo pathway by targeting YAP1/TEAD4-CTGF axis in gastric carcinogenesis. Kang W; Huang T; Zhou Y; Zhang J; Lung RWM; Tong JHM; Chan AWH; Zhang B; Wong CC; Wu F; Dong Y; Wang S; Yang W; Pan Y; Chak WP; Cheung AHK; Pang JCS; Yu J; Cheng ASL; To KF Cell Death Dis; 2018 Jan; 9(2):92. PubMed ID: 29367737 [TBL] [Abstract][Full Text] [Related]
14. Atypical protein kinase C induces cell transformation by disrupting Hippo/Yap signaling. Archibald A; Al-Masri M; Liew-Spilger A; McCaffrey L Mol Biol Cell; 2015 Oct; 26(20):3578-95. PubMed ID: 26269582 [TBL] [Abstract][Full Text] [Related]
15. Mu-KRAS attenuates Hippo signaling pathway through PKCι to sustain the growth of pancreatic cancer. Wang P; Zhang H; Yang J; Li Z; Wang Y; Leng X; Ganapathy S; Isakson P; Chen C; Zhu T J Cell Physiol; 2020 Jan; 235(1):408-420. PubMed ID: 31230347 [TBL] [Abstract][Full Text] [Related]
16. Opposing activities of the Ras and Hippo pathways converge on regulation of YAP protein turnover. Hong X; Nguyen HT; Chen Q; Zhang R; Hagman Z; Voorhoeve PM; Cohen SM EMBO J; 2014 Nov; 33(21):2447-57. PubMed ID: 25180228 [TBL] [Abstract][Full Text] [Related]
17. Angiomotin promotes breast cancer cell proliferation and invasion. Lv M; Lv M; Chen L; Qin T; Zhang X; Liu P; Yang J Oncol Rep; 2015 Apr; 33(4):1938-46. PubMed ID: 25647626 [TBL] [Abstract][Full Text] [Related]
18. LATS2-mediated YAP1 phosphorylation is involved in HCC tumorigenesis. Guo C; Wang X; Liang L Int J Clin Exp Pathol; 2015; 8(2):1690-7. PubMed ID: 25973055 [TBL] [Abstract][Full Text] [Related]
19. Low angiomotin-p130 with concomitant high Yes-associated protein 1 expression is associated with adverse prognosis of advanced gastric cancer. Hong SA; Son MW; Cho J; Jang SH; Lee HJ; Lee JH; Cho HD; Oh MH; Lee MS APMIS; 2017 Nov; 125(11):996-1006. PubMed ID: 28885730 [TBL] [Abstract][Full Text] [Related]
20. RASAL2 promotes tumor progression through LATS2/YAP1 axis of hippo signaling pathway in colorectal cancer. Pan Y; Tong JHM; Lung RWM; Kang W; Kwan JSH; Chak WP; Tin KY; Chung LY; Wu F; Ng SSM; Mak TWC; Yu J; Lo KW; Chan AWH; To KF Mol Cancer; 2018 Jul; 17(1):102. PubMed ID: 30037330 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]